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The understanding of mitochondria and their quality 
control in cancer genesis and progression is increasing 
exponentially. While the Warburg hypothesis depicts 
mitochondria as silent within a glycolytic tumorigenic 
environment, it is now known that in malignant cells 
mitochondria are constitutively active, priming malignant 
reprogramming and promoting survival. Thus, in cancer 
cells mitochondria supply energy, provide building 
blocks for new cells, control redox homeostasis and 
define oncogenic signals commanding programmed cell 
death [1]. Two other aspects of mitochondrial physiology 
have been relatively unexplored in the context of cancer 
pathogenesis: mitochondrial biogenesis and autophagic 
degradation for quality control. These two biological 
processes work together to regulate mitochondrial mass, 
morphology and function to accumulate or eliminate 
mitochondria for the purpose of cell progression. 
Furthermore, cross-analysis of the mitochondrial genomes 
in various cancers has revealed that there is a negative 
selection for pathogenic mtDNA mutations, suggesting 
an active engagement of mechanisms for mitochondrial 
removal within clinical cancers [1, 2]. The work by Biel 
and Rao highlights mitophagy as an efficient mechanism 
of chemotherapy resistance, demanding further attention 
on this process to inform innovative approaches of 
therapeutic value [3]. Targeting mitochondria as an 
anti-cancer strategy has historically provided obstacles 
to successful therapy. This is due to the development 
of resistance phenomena such as those ascribed to the 
exploitation of the mitochondrial retrograde response, 
questioning whether mitophagy should have the opposite 
effect.
Intrinsic aspects of mitochondrial function in cancer 
cells allow for the selective targeting of tumorigenic 
cells, including differences in mitochondrial membrane 
potential (∆ψm) which provides a putative target for anti-
cancer therapy. Mitochondrial redox molecules conjugated 
to triphenylphosphonium (TPP) exploit such differences 
and accumulate within the mitochondria as a selective 
therapeutic approach. 
Biel and Rao, describe how these TPP-conjugated 
antioxidants trigger a mitophagy-mediated resistance 
mechanism [3]. The role of mitophagy in tumorigenesis 
and cancer cell survival is likely to be context-dependent, 
controlled by the metabolic demands and stage of the 
tumour. Prior to neoplastic transformation, mitophagy is 
generally considered anti-tumorigenic, used by the healthy 
cell to selectively degrade dysfunctional mitochondria 
and prevent the accumulation of tumour-promoting 
reactive oxygen species (ROS) [4]. However, during 
conditions where mitochondria are chemically targeted 
to induce selective cellular demise mitophagy may act as 
a pro-survival mechanism, thereby removing the targets 
necessary for this strategic intervention [4]. 
The pharmacological control of mitophagy could 
in turn be tested as a way to improve the therapeutic 
efficacy of chemotherapy. Hitherto, few selective non-
toxic inducers of mitophagy have been developed, i.e. 
Urolithin A [5] and the p62-mediated mitophagy inducer 
(PMI) [6] but pharmacological protocols to prevent 
mitophagy are yet to be developed. This could clearly 
be beneficial to aid therapy undermined by hyperactive 
mitophagy. Interestingly, anti-mitophagy molecules such 
as the mitochondrial translocator protein (TSPO) are 
overexpressed in aggressive forms of cancer implying 
that molecular regulation of mitophagy is embedded in 
the pathophysiology of the disease. According to Biel 
and Rao, mitophagy is induced solely in the aggressive 
breast cancer cell line MDA-MB-231 and not in the 
primary mammary epithelial cells (MCF-12A). Sub-
lethal concentrations of TPP-conjugated redox molecules, 
including mitoquinone (MitoQ) and mitoApocynin 
(MitoA) exploit the increased ∆ψm reported in aggressive 
cancer cells leading to sustained mitophagy [3]. The 
authors elegantly provide evidence for the mitophagy-
mediated resistance to chemotherapy that occurs via the 
canonical PINK1-Parkin pathway [3]. Interestingly, by 
playing with chemical inhibitors of the autophagy cascade, 
they detect the presence of basal mitophagic activity in 
MCF-12A, absent in MDA-MB-231. 
This work re-invigorates the field of mitophagy in 
the progression and management of tumours. Discovering 
whether mitophagy induction is a feature of less aggressive 
cancer cells could unveil the culling of non-abiding 
mitochondria as a mechanism to reprogram cells towards 
metastatic tendencies. Conclusively, this research brings 
into focus mitochondrial life-cycle modulation as a key 
effector in cancer cell divergence and reveals therapeutic 
implications for the pharmacological fine-tuning of 
mitophagy to overcome chemotherapy resistance [7]. 
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